8 results
6-K
EX-99.1
SPRC
SciSparc Ltd.
20 Aug 24
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
7:00am
with our mission of improving people’s lives, we are happy with the ongoing pace of enrollment in the SCI-210 trial and expect that this study
6-K
EX-99.1
SPRC
SciSparc Ltd.
29 Jan 24
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
4:00pm
at SciSparc as it aligns with our mission to improve human health through the development of novel therapies,” said SciSparc’s Chief Executive Officer
6-K
EX-99.1
SPRC
SciSparc Ltd.
11 Aug 22
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:42am
with CannAmide™, a mission always desirable but even more so when children are the target population.”
The trial will investigate the effect of the Company’s
6-K
EX-99.1
SPRC
SciSparc Ltd.
24 Jun 22
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:52am
with CannAmide™, a mission always desirable but even more so when children are the target population.”
ASD is a condition related to brain development
6-K
EX-99.1
SPRC
SciSparc Ltd.
23 Jun 20
Annual and Special General Meeting of Shareholders
9:06am
in the Company. The Company defined three key points to the shareholders:
The Company’s 2020 corporate vision and mission of the company;
The Company’s
6-K
sae69 lkn
23 Jun 20
Annual and Special General Meeting of Shareholders
9:06am
6-K
EX-99.2
enpzv
22 Apr 20
Therapix Biosciences Announces Appointment of New CEO
5:30pm
6-K
EX-99.1
ljknkut
24 Oct 18
Report of Foreign Private Issuer
6:45am
- Prev
- 1
- Next